• Increase
  • Decrease
  • Normal

Current Size: 100%

Ed Forum 2017

IWMF to Livestream Dr. Steven Treon from the Ed Forum

May 23, 2019

Announcing… SATURDAY AFTERNOON LIVE!
World Leader in the Waldenströ
m’s Revolution

Dr. Steven P. Treon, MD, PhD

STREAMING LIVE ONLINE

From the 2019 IWMF Ed Forum in Philadelphia
Saturday, June 8, 2:20-3:30 pm US EDT

”Breaking News from the Front: IWWM-10 & the IWMF-LLS Strategic Research Roadmap Summit”

Dr. Treon is Principal Organizer of the International Workshops on Waldenström’s Macroglobulinemia (IWWM) and Scientific Co-Chair of several IWMF-LLS Strategic Research Roadmap Summits
Don’t miss this opportunity to learn from a leading world-class WM researcher and clinician!

Presentation Details

Dr. Treon will be presenting the latest updates in research and treatments for WM, based on IWWM-10 and IWMF-LLS Strategic Research Roadmap Summit proceedings. This promises to be an engaging and informative presentation, whereby Dr. Treon will share his insights and the collective insights of renowned researchers from around the world, as he discusses the latest progress toward better treatment methods and the path toward arriving at a revolutionary cure for WM!

How to Watch the Presentation

Dr. Treon’s live presentation will be streamed online on Saturday, June 8, from 2:20PM 3:30 PM on two platforms. You can view it at either:
YouTubeyoutube.com/user/IWMFVideos, or
Facebook (you need a Facebook account to view it): facebook.com/waldenstroms.support

NOTE: If you encounter technical problems during the day of the presentation, contact Jeremy Dictor at jdictor@iwmf.com, and he will assist.

Speaker Bio
Dr. Steven Treon is Director of the Bing Center for Waldenström’s Macroglobulinemia at the Dana-Farber Cancer Institute in Boston, Professor of Medicine at Harvard Medical School, Chair of the WM Clinical Trials Group, and Principal Organizer of the International Workshops on WM (IWWM). Dr. Treon and his laboratory, through whole genome sequencing, were the first to discover the MYD88 mutation in WM, occurring in 95% of WM patients, and the presence and significance of CXCR4 mutations in WM. He was the Principal Investigator on the pivotal trial that led to the first-ever approval of a drug for WM, ibrutinib (Imbruvica), by the US Food and Drug Administration and the European Medicines Agency. He is the recipient of the Robert A. Kyle Award for Outstanding Contributions to WM, and the Jan Gösta Waldenström Lifetime Achievement Award, and was elected a Fellow of the Royal College of Physicians in London and a fellow of the American College of Physicians for his work on WM. You can read Dr. Treon's complete biography here.

 

 

 

Section: